R M Phillips
Overview
Explore the profile of R M Phillips including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohamed H, Khuphe M, Boardman S, Shepherd S, Phillips R, Thornton P, et al.
RSC Adv
. 2022 May;
8(19):10474-10477.
PMID: 35540495
Amphiphilic block copolymers have been developed for the encapsulation of organometallic drugs. silver-N-heterocyclic carbene complexes have shown significant promise as anticancer and antibacterial compounds, and have been studied as the...
2.
Jove M, Spencer J, Hubbard M, Holden E, ODea R, Brook B, et al.
J Pharmacol Exp Ther
. 2019 Jun;
370(2):242-251.
PMID: 31189729
Adequate drug distribution through tumors is essential for treatment to be effective. Palbociclib is a cyclin-dependent kinase 4/6 inhibitor approved for use in patients with hormone receptor positive, human epidermal...
3.
Phillips R, Hendriks H, Sweeney J, Reddy G, Peters G
Expert Opin Drug Metab Toxicol
. 2017 Jun;
13(7):783-791.
PMID: 28637373
Apaziquone (also known as EO9 and Qapzola) is a prodrug that is activated to DNA damaging species by oxidoreductases (particularly NQO1) and has the ability to kill aerobic and/or hypoxic...
4.
Hubbard M, Jove M, Loadman P, Phillips R, Twelves C, Smye S
R Soc Open Sci
. 2017 Jun;
4(5):170014.
PMID: 28573005
The tumour vasculature and microenvironment is complex and heterogeneous, contributing to reduced delivery of cancer drugs to the tumour. We have developed an model of drug transport in a tumour...
5.
Rodriguez-Barzano A, Lord R, Basri A, Phillips R, Blacker A, McGowan P
Dalton Trans
. 2015 Jan;
44(7):3265-70.
PMID: 25597645
The complexes [RuCp*(PP)Cl] (Cp* = C5Me5; [], PP = dppm; [], PP = Xantphos), [RuCp(#)(PP)Cl] (Cp(#) = C5Me4(CH2)5OH; [], PP = dppm; [], PP = Xantphos) and [RuCp*(dppm)(CH3CN)][SbF6] [] were...
6.
Allison S, Knight J, Granchi C, Rani R, Minutolo F, Milner J, et al.
Oncogenesis
. 2014 May;
3:e102.
PMID: 24819061
Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer's glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD(+)) from...
7.
Groh C, Hubbard M, Jones P, Loadman P, Periasamy N, Sleeman B, et al.
J R Soc Interface
. 2014 Mar;
11(94):20131173.
PMID: 24621814
The ability to predict how far a drug will penetrate into the tumour microenvironment within its pharmacokinetic (PK) lifespan would provide valuable information about therapeutic response. As the PK profile...
8.
Ahmadi M, Ahmadihosseini Z, Allison S, Begum S, Rockley K, Sadiq M, et al.
Br J Pharmacol
. 2013 Oct;
171(1):224-36.
PMID: 24117380
Background And Purpose: Hypoxia in tumours is known to cause resistance to conventional chemotherapeutic drugs. In contrast, little is known about the effects of hypoxia on targeted anti-cancer drugs. This...
9.
Phillips R, Goldstein M, Hougland K, Nandyal R, Pizzica A, Santa-Donato A, et al.
J Perinatol
. 2013 Jun;
33 Suppl 2:S5-22.
PMID: 23803627
No abstract available.
10.